International Private Investors

International Private Investors is a biotechnology company specializing in the field of cancer virotherapy. The company is the primary developer and rights holder of Rigvir, an oncolytic virus derived from the ECHO-7 strain, which is designed to infect and lyse tumor cells while inducing an anti-tumor immune response. Rigvir gained regulatory approval in Latvia for the treatment of melanoma and has been used in several other countries under various regulatory frameworks. International Private Investors oversees the manufacturing, further clinical research, and global distribution of its virotherapy products, positioning itself as a pioneer in the clinical application of oncolytic viruses. Despite regulatory challenges in recent years, the company continues to support the use of virotherapy in oncology.